Ascendis Pharma Q1 2026 revenue jumps to €247M, driven by strong YORVIPATH sales and new FDA approval for YUVIWEL.

Ascendis Pharma reported strong first quarter 2026 results with total revenue of €247 million, up significantly from €101 million in Q1 2025, mainly due to increased sales of YORVIPATH. The company also received FDA accelerated approval for YUVIWEL, a treatment for children with achondroplasia, with over 60 patient enrollments since its U.S. launch in April 2026. Ascendis plans to expand YUVIWEL's market in Europe and continue clinical trials for label expansions and new therapies. The company also sold a Rare Pediatric Disease Priority Review Voucher for $187.5 million, boosting its financial position alongside strong operating profit and net profit driven by deferred tax asset recognition.